1. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda 
Mary K Grabowski, PhD, Prof Ronald H Gray, MD, Fred Makumbi, PhD, Joseph Kagaayi, MBChB, Andrew D Redd, PhD, Godfrey Kigozi, MBChB, Steven J Reynolds, MD, Fred Nalugoda, MHS, Tom Lutalo, MS, Prof Maria J Wawer, MD, Prof David Serwadda, MD, Prof Thomas C Quinn, MD, Aaron A R Tobian, MD 
The Lancet Global Health 
Volume 3, Issue 8, Pages e478-e486 (August 2015)
DOI: /S X(15)
Copyright © 2015 Grabowski et al. Open access article published under the terms of CC BY-NC-ND Terms and Conditions

2. Figure
Patterns of hormonal contraceptive use over 2 years and HSV2 incidence
(A) Individual-level patterns of hormonal contraceptive use between enrolment and year 2 study visits for a random sample of 50 hormonal contraceptive users. (B) Classification of exposure to hormonal contraception for a visit interval using contraceptive and pregnancy statuses from the present and previous study visits. DMPA=depo-medroxyprogesterone acetate. HC=hormonal contraception. HSV2=herpes simplex virus type 2. t–1=previous visit. t=present visit. *No woman switched from DMPA to oral HC.
The Lancet Global Health 2015 3, e478-e486DOI: ( /S X(15) )
Copyright © 2015 Grabowski et al. Open access article published under the terms of CC BY-NC-ND Terms and Conditions